Clinical Remission of Rheumatoid Arthritis in a Multicenter Real-World Study in Asia-Pacific Region

Background: Clinical remission is an attainable goal for Rheumatoid Arthritis (RA). However, data on RA remission rates in Asia-Pacific region are lacking. We conducted a cross-sectional study to evaluate the clinical remission status and the associated factors in RA patients in Asia-Pacific region. Methods: RA patients receiving standard care were enrolled consecutively from 17 sites in 11 countries. Data were collected on-site by rheumatologists with a standardized case-report form. Remission was analyzed by different definitions including disease activity score using 28 joints (DAS28) based on ESR and CRP, clinical disease activity index (CDAI), simplified disease activity index (SDAI), Boolean remission definition, and clinical deep remission (CliDR). Logistic regression was used to determine associated factors of remission. Findings: A total of 2010 RA patients was included in the study, the overall remission rates were 62·31% (DAS28-CRP), 35·51% (DAS28-ESR), 30·78% (CDAI), 26·50% (SDAI), 24·71% (Boolean), and 17·06% (CliDR), respectively, and varied from sites to sites in the 11 countries. Biological disease-modifying antirheumatic drugs (bDMARDs) prescription rate was low (16·9%). Compared to patients in non-remission, patients in remission had higher rates of csDMARDs monotherapy, bDMARDs usage and lower rates of GC usage. The favorable factors were male sex, younger age, fewer comorbidities, less extra-articular manifestations (EAM), and use of bDMARDs, while treatment with GC was negatively associated with remission. Interpretation: Remission rates were low and varied in the Asia-Pacific region. Treatment with bDMARDs and less GC usage were related to higher remission rate. There is an unmet need for RA remission in the Asia-Pacific region. Funding Information: Beijing Municipal Science and Technology Project (Z191100006619110), Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking-Tsinghua Center for Life Sciences. Declaration of Interests: None. Ethics Approval Statement: The study was approved by the ethics committee of each center.